Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production.

Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, Chioma OS, Lee G, Hassell NE, Shaginurova GI, Wang Y, Johnson JE, Kerrigan A, Mason WR, Baughman RP, Ayers GD, Bernard GR, Culver DA, Montgomery CG, Maher TM, Molyneaux PL, Noth I, Mutsaers SE, Prele CM, Peebles RS Jr, Newcomb DC, Kaminski N, Blackwell TS, Van Kaer L, Drake WP.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaar8356. doi: 10.1126/scitranslmed.aar8356.

PMID:
30257954
2.

Regularized Latent Class Model for Joint Analysis of High Dimensional Longitudinal Biomarkers and A Time-to-Event Outcome.

Sun J, Herazo-Maya JD, Molyneaux PL, Maher TM, Kaminski N, Zhao H.

Biometrics. 2018 Sep 3. doi: 10.1111/biom.12964. [Epub ahead of print]

PMID:
30178494
3.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

PMID:
30170904
4.

Review of the British Thoracic Society Winter Meeting 2017, 6-8 December 2017, London, UK.

Singanayagam A, Woodcock HV, Molyneaux PL, Jenkins G.

Thorax. 2018 Sep;73(9):872-876. doi: 10.1136/thoraxjnl-2018-212012. Epub 2018 Jun 14.

5.

Could quality be the key in connective tissue disease-associated interstitial lung disease?

Molyneaux PL, Maher TM.

Respirology. 2018 Jun 13. doi: 10.1111/resp.13340. [Epub ahead of print] No abstract available.

PMID:
29897157
6.

Clinical Genetics in Interstitial Lung Disease.

Newton CA, Molyneaux PL, Oldham JM.

Front Med (Lausanne). 2018 Apr 26;5:116. doi: 10.3389/fmed.2018.00116. eCollection 2018. Review.

7.

Rapidly Progressive Cystic Lung Disease.

Rogers C, Kent-Bramer J, Devaraj A, Nicholson AG, Molyneaux PL, Wells AU, Saikia S, Maher TM, George PM.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):264. doi: 10.1164/rccm.201801-0161IM. No abstract available.

8.

Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease.

Mallia P, Webber J, Gill SK, Trujillo-Torralbo MB, Calderazzo MA, Finney L, Bakhsoliani E, Farne H, Singanayagam A, Footitt J, Hewitt R, Kebadze T, Aniscenko J, Padmanaban V, Molyneaux PL, Adcock IM, Barnes PJ, Ito K, Elkin SL, Kon OM, Cookson WO, Moffat MF, Johnston SL, Tregoning JS.

J Allergy Clin Immunol. 2018 Sep;142(3):815-823.e6. doi: 10.1016/j.jaci.2017.10.017. Epub 2018 Jan 5.

9.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG.

Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14.

10.

Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.

Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, Guillen-Guio B, Ma SF, Okamoto T, John AE, Obeidat M, Yang IV, Henry A, Hubbard RB, Navaratnam V, Saini G, Thompson N, Booth HL, Hart SP, Hill MR, Hirani N, Maher TM, McAnulty RJ, Millar AB, Molyneaux PL, Parfrey H, Rassl DM, Whyte MKB, Fahy WA, Marshall RP, Oballa E, Bossé Y, Nickle DC, Sin DD, Timens W, Shrine N, Sayers I, Hall IP, Noth I, Schwartz DA, Tobin MD, Wain LV, Jenkins RG.

Lancet Respir Med. 2017 Nov;5(11):869-880. doi: 10.1016/S2213-2600(17)30387-9. Epub 2017 Oct 20.

11.

Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study.

Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, Lynn H, Juan-Guardela BM, Risquez C, Osorio JC, Yan X, Michel G, Aurelien N, Lindell KO, Klesen MJ, Moffatt MF, Cookson WO, Zhang Y, Garcia JGN, Noth I, Prasse A, Bar-Joseph Z, Gibson KF, Zhao H, Herzog EL, Rosas IO, Maher TM, Kaminski N.

Lancet Respir Med. 2017 Nov;5(11):857-868. doi: 10.1016/S2213-2600(17)30349-1. Epub 2017 Sep 21.

12.

Time for an International Consensus on Hypersensitivity Pneumonitis. A Call to Arms.

Molyneaux PL, Maher TM.

Am J Respir Crit Care Med. 2017 Sep 15;196(6):665-666. doi: 10.1164/rccm.201707-1439ED. No abstract available.

PMID:
28723313
13.

The respiratory microbiome in idiopathic pulmonary fibrosis.

Hewitt RJ, Molyneaux PL.

Ann Transl Med. 2017 Jun;5(12):250. doi: 10.21037/atm.2017.01.56. Review.

14.

Microbiome in interstitial lung disease: from pathogenesis to treatment target.

Salisbury ML, Han MK, Dickson RP, Molyneaux PL.

Curr Opin Pulm Med. 2017 Sep;23(5):404-410. doi: 10.1097/MCP.0000000000000399. Review.

15.

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.

Conforti F, Davies ER, Calderwood CJ, Thatcher TH, Jones MG, Smart DE, Mahajan S, Alzetani A, Havelock T, Maher TM, Molyneaux PL, Thorley AJ, Tetley TD, Warner JA, Packham G, Ganesan A, Skipp PJ, Marshall BJ, Richeldi L, Sime PJ, O'Reilly KMA, Davies DE.

Oncotarget. 2017 Jul 25;8(30):48737-48754. doi: 10.18632/oncotarget.17114.

16.

The microbiome in respiratory medicine: current challenges and future perspectives.

Faner R, Sibila O, Agustí A, Bernasconi E, Chalmers JD, Huffnagle GB, Manichanh C, Molyneaux PL, Paredes R, Pérez Brocal V, Ponomarenko J, Sethi S, Dorca J, Monsó E.

Eur Respir J. 2017 Apr 12;49(4). pii: 1602086. doi: 10.1183/13993003.02086-2016. Print 2017 Apr. Review.

17.

Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis.

Molyneaux PL, Cox MJ, Wells AU, Kim HC, Ji W, Cookson WO, Moffatt MF, Kim DS, Maher TM.

Respir Res. 2017 Feb 1;18(1):29. doi: 10.1186/s12931-017-0511-3.

18.

Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis.

Molyneaux PL, Willis-Owen SAG, Cox MJ, James P, Cowman S, Loebinger M, Blanchard A, Edwards LM, Stock C, Daccord C, Renzoni EA, Wells AU, Moffatt MF, Cookson WOC, Maher TM.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1640-1650. doi: 10.1164/rccm.201607-1408OC.

19.

Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia.

Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Murphy E, Smith K, McKean D, Pedersen BS, Talbert J, Powers J, Markin CR, Beckman KB, Lathrop M, Freed B, Langefeld CD, Schwartz DA.

BMC Genet. 2016 Jun 7;17(1):74. doi: 10.1186/s12863-016-0377-2.

20.

Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis.

Russell AM, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, Wells AU, Maher TM.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):989-997.

21.

Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.

Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R, Molyneaux PL, McKeever TM, Wells AU, Flynn A, Hubbard RB, Leeming DJ, Marshall RP, Karsdal MA, Lukey PT, Maher TM.

Lancet Respir Med. 2015 Jun;3(6):462-72. doi: 10.1016/S2213-2600(15)00048-X. Epub 2015 Mar 12.

22.

The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis.

Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, Murphy E, Johnston SL, Schwartz DA, Wells AU, Cookson WO, Maher TM, Moffatt MF.

Am J Respir Crit Care Med. 2014 Oct 15;190(8):906-13. doi: 10.1164/rccm.201403-0541OC.

23.

Respiratory microbiome in IPF: cause, effect, or biomarker?

Molyneaux PL, Maher TM.

Lancet Respir Med. 2014 Jul;2(7):511-3. doi: 10.1016/S2213-2600(14)70088-8. Epub 2014 Apr 21. No abstract available.

PMID:
24767768
24.

Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphadenopathy by endobronchial ultrasound.

Dhasmana DJ, Ross C, Bradley CJ, Connell DW, George PM, Singanayagam A, Jepson A, Craig C, Wright C, Molyneaux PL, Wickremasinghe M, Lalvani A, Cooke GS, Kon OM.

Ann Am Thorac Soc. 2014 Mar;11(3):392-6. doi: 10.1513/AnnalsATS.201308-250OC.

25.

The role of infection in the pathogenesis of idiopathic pulmonary fibrosis.

Molyneaux PL, Maher TM.

Eur Respir Rev. 2013 Sep 1;22(129):376-81. doi: 10.1183/09059180.00000713. Review.

26.

Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.

Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis-Owen SA, Homola D, Trujillo-Torralbo MB, Elkin S, Kon OM, Cookson WO, Moffatt MF, Johnston SL.

Am J Respir Crit Care Med. 2013 Nov 15;188(10):1224-31. doi: 10.1164/rccm.201302-0341OC.

27.

Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy.

Singanayagam A, Manalan K, Sridhar S, Molyneaux PL, Connell DW, George PM, Kindelerer A, Seneviratne S, Lalvani A, Wickremasinghe M, Kon OM.

Thorax. 2013 Oct;68(10):955-61. doi: 10.1136/thoraxjnl-2013-203436. Epub 2013 Aug 23.

28.

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.

Woodcock HV, Molyneaux PL, Maher TM.

Drug Des Devel Ther. 2013 Jun 19;7:503-10. doi: 10.2147/DDDT.S38833. Print 2013. Review.

29.

Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.

Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen BS, Talbert J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz MI, Schwartz DA.

Nat Genet. 2013 Jun;45(6):613-20. doi: 10.1038/ng.2609. Epub 2013 Apr 14. Erratum in: Nat Genet. 2013 Nov;45(11):1409.

30.

Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis.

Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, Abraham DJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Lindahl GE, Renzoni EA.

Thorax. 2013 May;68(5):436-41. doi: 10.1136/thoraxjnl-2012-201786. Epub 2013 Jan 15.

PMID:
23321605
31.

Lung microbiology and exacerbations in COPD.

Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P.

Int J Chron Obstruct Pulmon Dis. 2012;7:555-69. doi: 10.2147/COPD.S28286. Epub 2012 Aug 31. Review.

32.

A presentation of Poncet's disease identified following immunosuppressive steroid therapy.

Kasivisvanathan V, Connell DW, Molyneaux PL, Singanayagam A, George PM, Tench C, Kon OM.

Int J Tuberc Lung Dis. 2012 May;16(5):708-9. doi: 10.5588/ijtld.11.0749. No abstract available.

PMID:
22507942
33.

A comparison between two strategies for monitoring hepatic function during antituberculous therapy.

Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell DW, George PM, Molyneaux PL, Cooke GS, Burroughs AK, Lalvani A, Wickremasinghe M, Kon OM.

Am J Respir Crit Care Med. 2012 Mar 15;185(6):653-9. doi: 10.1164/rccm.201105-0850OC. Epub 2011 Dec 28.

PMID:
22198973
34.

Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopathy: a multicentre study.

Navani N, Molyneaux PL, Breen RA, Connell DW, Jepson A, Nankivell M, Brown JM, Morris-Jones S, Ng B, Wickremasinghe M, Lalvani A, Rintoul RC, Santis G, Kon OM, Janes SM.

Thorax. 2011 Oct;66(10):889-93. doi: 10.1136/thoraxjnl-2011-200063. Epub 2011 Aug 3.

35.

A comparison between interferon gamma release assays and the tuberculin skin test in the contact tracing of patients with chronic kidney disease.

Connell DW, Singanayagam A, Charif R, George PM, Molyneaux PL, McCrudden C, Magtoto M, Harden E, Seneviratne SL, Duncan ND, Kon OM.

Thorax. 2011 Aug;66(8):729-30; author reply 730. doi: 10.1136/thx.2010.149088. Epub 2010 Oct 14. No abstract available.

PMID:
20947898

Supplemental Content

Loading ...
Support Center